Producers, Others Say Aussie PBS Still Not Covering Cost-Effective Drugs
This article was originally published in PharmAsia News
Drug makers and Australian patient groups are pressuring the nation’s Pharmaceutical Benefits Scheme to fulfill a promise made nearly a year ago to resume automatic coverage of drugs forecast to cost the scheme less than U.S.$10.5 million year.
You may also be interested in...
Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.
Separate concerns raised by the EMA over bioequivalence studies have led Mylan and Accord to withdraw generic applications, including the former’s generic version of Gilenya for the treatment of multiple sclerosis.
New York's Avista Capital Partners has taken a 50% stake in Belgian consumer health player Vision Healthcare, which has its sights set on the US market.